Carafate 1g/10ml Suspension - 420ml / 14oz Bottle We will be closed on Monday 9/7/20 for Labor Day, we will resume normal business hours on Tuesday 9/8/20 at 8am Eastern Standard Time. Because many drugs are excreted in human milk, caution should be (See This drug is known to be substantially excreted by the US, Inc., 100 Somerset Corporate Boulevard, Bridgewater, NJ 08807, USA. Do not take antacids 30 minutes before or after taking Carafate (sucralfate oral suspension).

In addition, aluminum does not cross dialysis membranes because it is bound to albumin and transferrin plasma proteins. insoluble excipients has led to fatal complications, including pulmonary and There are approximately 14 to 16 mEq of acid-neutralizing capacity per 1 g dose of sucralfate.In a multicenter, double-blind, placebo-controlled study of Carafate Oral Suspension, a dosage regimen of 1 gram (10 mL) four times daily was demonstrated to be superior to placebo in ulcer healing.Equivalence of sucralfate oral suspension to sucralfate tablets has not been demonstrated.Carafate (sucralfate) Oral Suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer.Carafate Oral Suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.Fatal complications, including pulmonary and cerebral emboli have occurred with inappropriate intravenous administration of Carafate Oral Suspension. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (See This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function (See Cases of bronchospasm, laryngeal edema and respiratory tract edema have been reported with an unknown oral formulation of sucralfate.Cases of hyperglycemia have been reported with sucralfate.Bezoars have been reported in patients treated with sucralfate. If there is none, ask the pharmacist for a device to measure Carafate (sucralfate oral suspension).

suspension supplied in bottles of 14 fl oz (Store at controlled room temperature 20-25°C evidence of harm to the fetus due to sucralfate. Available for Android and iOS devices.

and well-controlled studies in pregnant women. Studies in human subjects and with animal models of ulcer disease have shown that sucralfate forms an ulcer-adherent complex with proteinaceous exudate at the ulcer site.3. methylparaben NF, microcrystalline cellulose NF, purified water USP, simethicone Aluminum accumulation and toxicity (aluminum osteodystrophy, osteomalacia, encephalopathy) have been described in patients with renal impairment. usually starting at the low end of the dosing range, reflecting the greater

Patients with chronic renal failure or those receiving dialysis have impaired excretion of absorbed aluminum. You may report side effects to Aptalis Pharma US, Inc. at 1-800-472-2634 or FDA Revised: Apr 2014.Adverse reactions to sucralfate tablets in clinical Other reported clinical experience has not identified differences in responses between the elderly and younger patients. milk. dioxide NF, FD&C Red #40, flavor, glycerin USP, methylcellulose USP, Other Those few reports where adverse events were described included symptoms of dyspepsia, abdominal pain, nausea, and vomiting.Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after Carafate Oral Suspension.While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.Call your doctor for medical advice about side effects. CARAFATE ® (sucralfate) Suspension 1 g/10 mL is a pink suspension supplied in bottles of 14 fl oz (NDC 54868-3735-0). administration in healthy volunteers reduced the extent of absorption

A reproduction study in rats at doses up to 38 times the human dose did not reveal any indication of fertility impairment. conducted in mice and rats at doses up to 1 g/kg (12 times the human dose).There was no evidence of drug-related tumorigenicity.

In human subjects, sucralfate given in doses recommended for ulcer therapy inhibits pepsin activity in gastric juice by 32%.These observations suggest that sucralfate’s antiulcer activity is the result of formation of an ulcer- adherent complex that covers the ulcer site and protects it against further attack by acid, pepsin, and bile salts.